Robust and cost-effective CRISPR/Cas9 gene editing of primary tumor B cells in Eµ-TCL1 model of chronic lymphocytic leukemia

Hemasphere. 2024 Aug 15;8(8):e134. doi: 10.1002/hem3.134. eCollection 2024 Aug.

Authors

Rosita Del Prete¹, Roberta Drago^{1

2}, Federica Nardi¹, Gaia Bartolini¹, Erika Bellini¹, Antonella De Rosa¹, Silvia Valensin¹, Anna Kabanova¹

Affiliations

¹ Fondazione Toscana Life Sciences Siena Italy.
² PhD Program in Translational and Precision Medicine University of Siena Siena Italy.

No abstract available